Recombinant Albumin Fusion Proteins

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 163-178

  Weimer, Thomas ^a   Metzner, Hubert J ^a   Schulte, Stefan ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Albumin FPs; FVII and FIX; Glucagon like peptide 1; Recombinant albumin FPs; Successes failures

Indexed keywords

EID: 84886127949     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch10     Document Type: Chapter

References (95)

1. Werle M, Bernkop-Schnurch A. (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351-367.
2. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. (2007) Albinterferon a-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25, 1411-1419.
3. Andersen JT, Sandlie, I. (2009) The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacokinet. 24, 318-332.
4. Kontermann RE. (2009) Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23, 93-109.
5. Meloun B, Moravek L, Kostka V. (1975) Complete amino acid sequence of human serum albumin. FEBS Lett. 58, 134-137.
6. Chuang VT, Kragh-Hansen U, Otagiri M. (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharmaceut. Res. 19, 569-577.
7. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. (2006) Perspective: FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 27, 343-348.
8. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315-322.
9. Chemmanur AT, Wu GY. (2006) Drug evaluation: albuferonalpha-an antiviral interferon-alpha/albumin fusion protein. Curr. Opin. Invest. Drugs 7, 750-758.
10. Schulte, S. (2008) Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb. Res.(Suppl. 4), S14-S19.
11. Weimer T,WormsbacherW, Kronthaler U, LangW, Liebing U, Schulte S. (2008) Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb. Haemost. 99, 659-667.
12. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb. Haemost. 102, 634-644.
13. Schmidt SR. (2009) Fusion-proteins as biopharmaceuticals-applications and challenges. Curr. Opin. Drug Discov. Devel. 12, 284-295.
14. Gao Z, Bai G, Chen J, Zhang Q, Pan, P, Bai F, et al. (2009) Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci. Biotechnol. Biochem. 73, 688-694.
15. Huang YS, Chen Z, Chen YQ, Ma GC, Shan JF, Liu W, et al. (2008) Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci. 14, 588-595.
16. Daly R, Hearn MT. (2005) Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J. Mol. Recognit. 18, 119-138.
17. Chen HH, Martin FL, Cataliotti A, Schirger JA, Burnett JC. (2007) AlbuBNP (Cardeva), a novel recombinant human Btype natriuretic peptide serum albumin fusion protein has prolonged renal enhancing properties when compared to human BNP. Circulation 116, II_284 [Abstract 1382].
18. Chen J-H, Zhang X-G, Jiang Y-T, Yan L-Y, Tang LO, Yin Y-W, et al. (2010) Bioactivity and pharmacokinetics of two human serum albumin-thymosin a1-fusion proteins, rHSA-Ta1 and rHSA-L-Ta1, expressed in recombinant Pichia pastoris. Cancer Immunol. Immunother. 59, 1335-1345.
19. Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE. (2007) Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 282, 12650-12660.
20. Dou W-F, Lei J-Y, Zhang L-F, Xu Z-H, Chen Y, Jin J. (2008) Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoria. Protein Expr. Purif. 61, 45-49.
21. HalpernW, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, et al. (2002) Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharmaceut. Res. 19, 1720-1729.
22. Tomkin GH. (2009) Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Therap. 11, 579-588.
23. Baggio LL, Huang Q, Brown TJ, Drucker DJ. (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53, 2492-2500.
24. Matthews JE, StewartMW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 4810-4817.
25. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandamouli V, et al. (2004) One week's treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a-and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53, 1187-1194.
26. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, et al. (2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44, 671-678.
27. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, et al. (2010) Albinterfeon alfa-2b was not inferior to pegylated interferon-a in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 139, 1257-1266.
28. WangW, Ou Y, Shi, Y. (2004) AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharmaceut. Res. 21, 2105-2111.
29. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, et al. (2002) Albutropin1: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol. 456, 149-158.
30. Yao Z, DaiW, Perry J, BrechbielMW, Sung C. (2004) Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol. Immunother. 53, 404-410.
31. Melder RJ, Osborn BL, Riccobene T, Kanakaraj P,Wei P, Chen G, et al. (2005) Pharmacokinetics and in vitro and in vivo antitumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother. 54, 535-547.
32. Evans L, Hughes M,Waters J, Cameron J, Dodsworth N, Tooth D, et al. (2010) The production, characterization and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr. Purif. 73, 113-124.
33. Marques JA, George JK, Smith IJ, Bhakta V, Sheffield WP. (2001) A barbourin-albumin fusion protein that is slowly REFERENCES 175 cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb. Haemost. 86, 902-908.
34. Huang YJ, Lundy PM, Lazaris A, Huang Y, Baldassarre H, Wang B, et al. (2008) Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol. 8, 50.
35. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, et al. (2008) A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33, 2715-2725.
36. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. (2008) An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem. Biol. Interact. 175, 83-87.
37. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, et al. (2006) Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol. 70, 1885-1891.
38. Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ, et al. (2009) Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr. Purif. 68, 137-145.
39. Zollner S, Weimer T, Schmidbauer S, Raquet E, Mueller-Cohrs J, Schulte S. (2010) Pharmacokinetics of a recombinant albumin-fused, human coagulation factor VIIa (rVIIa-FP) exhibiting prolonged serum half-life in different animal species. Haemophilia 16 (Suppl. 4), 33 [Abstract 07P24].
40. Syed S, Schuyler PD, Kulczycky M, Sheffield WP. (1997) Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 89, 3243-3252.
41. Hatton MW, Ross-Ouellet B. (1994) Radiolabeled r-hirudin as a measure of thrombin activity at, or within, the rabbit aorta wall in vitro and in vivo. Thromb. Haemost. 71, 499-506.
42. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, et al. (2010) Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121, 1510-1517.
43. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, et al. (2005) Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54, 251-258.
44. Cresto JC, Lavine RL, Buchly ML, Pnehos JC, Bhathena SJ, Recant L. (1977) Half-life of injected 125I-insulin in control and ob/ob mice. Acta Physiol. Latino Ame. 27, 7-15.
45. Ikuta S, Chuang VTG, Ishima Y, Nakajou K, Furukawa M, Watanabe H, et al. (2010) Albumin fusion of thioredoxin-the production and evaluation of its biological activity for potential therapeutic applications. J. Control. Rel. 147, 17-23.
46. Ancell CD, Phipps J, Young L. (2001) Thymosin alpha-1. Am. J. Health-Syst. Pharm. 58, 879-885.
47. Muller D, Schneider B, Pfizenmaier K, Wajant H. (2010) Superior serum half life of albumin tagged TNF ligands. Biochem. Biophys. Res. Commun. 396, 793-799.
48. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, GonSc ales F.L. Jr., et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982.
49. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
50. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, et al. (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferonalpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir. Ther. 11, 35-45.
51. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, et al. (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-a fusion protein in cynomolgus monkeys. J. Pharmacol.Exp. Ther. 303, 540-548.
52. Yeh P, Landais D, Lemaýtre M, Maury I, Crenne JY, Becquart J, et al. (1992) Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA 89, 1904-1908.
53. Perry CM, Jarvis B. (2001) Peginterferon-alpha-2a (40 kDa): a review of its use in the management of chronic hepatitis C. Drugs 61, 2263-2288.
54. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. (2000) Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68, 556-567.
55. Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, et al. (2009) Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C. J. Hepatol.(Suppl. 1), S378 [Abstract 1042].
56. Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir AJ, et al. (2009) Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 7, 212-218.
57. European Medicines Agency. Withdrawn Applications: Joulferon. Available at http://www.ema.europa.eu/ema/index.jsp?curl1/4pages/medicines/human/medicines/002166/wapp/Initial_ authorisation/human_wapp_000096.jsp&murl 1/4menus/ medicines/medicines.jsp&mid 1/4WC0b01ac058001d128&-source1/4homeMedSearch&category1/4human (last accessed September 23, 2010).
58. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. (2009) Albiglutide study group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. Diabetes Care 32, 1880-1886.
59. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402-7405.
60. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30, 1487-1493.
61. Jose B, Tahrani AA, Piya MK, Barnet AH. (2010) Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Prefer Adherence 4, 313-324.
62. Kim J-G, Baggio LL, Bridon DP, Castaigne J-P, Robitaille MF, Jette L, et al. (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52, 751-759.
63. Byetta prescribing information. Amylin Pharmaceuticals, Inc., September 2010. Available at http://pi.lilly.com/us/byetta-pi. pdf (last accessed October 1, 2010).
64. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, et al. (2002) Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25, 1398-1404.
65. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, et al. (2005) Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem. 16, 377-382.
66. Tanaka H, Satake-Ishikawa R, Ishikawa M, Matsuki S, Asano K. (1991) Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51, 3710-3714.
67. King AB, Armstrong D. (2003) A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine. Diabetes Care 26, 1322.
68. Haffner D, Schaefer F, Girard J, Ritz E, Mehis O. (1994) Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J. Clin. Invest. 93, 1163-1171.
69. Sheffield WP, Eltringham-Smith LJ, Gataiance S, Bhakta V. (2009) A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. Thromb. Haemost. 101, 867-877.
70. Markwardt F, Nowak G, St urzebecher J. (1991) Clinical pharmacology of recombinant hirudin. Haemostasis 21(Suppl. 1), 133-136.
71. Sheffield WP, Gataiance S, Eltringham-Smith LJ. (2007) Combined administration of barbourin-albumin and hirudin -albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta. Thromb. Res. 119, 195-207.
72. World Federation of Hemophilia (WFH). Guidelines for the Management of Hemophilia. Montreal: World Federation of Hemophilia; 2005. Available at http://www.wfh.org/2/docs/ Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia. pdf (last accessed May 25, 2010).
73. Hedner U, Ingerslev J. (1998) Clinical use of recombinant FVIIa (rFVIIa). Transfus. Sci. 19, 163-176.
74. Erhardtsen E. (2000) Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin. Thromb. Hemost. 26, 385-391.
75. Kronthaler U, Schmidbauer S, Liebing U, Lang W, Metzner HJ, Weimer T, et al. (2009) Prolonged half-life of recombinant factor VIIa fusion protein-single dose study in rabbits. XXII International Society on Thrombosis and Haemostasis Congress, Boston, USA, July 11-16, [Abstract P-TH-561]. Available at http://www.isth2009.com/poster_presentations_ thursday.html (last accessed May 25, 2010).
76. Horn C, Steuber H, Weimer T, Wormsbacher W, Liebing U, Kuo W-P. (2010) Concept and structure model of factor VIIa albumin fusion proteins. Haemophilia 16(Suppl. 4), 37 [Abstract 08P19].
77. White GC 2nd, Beebe A, Nielsen B. (1997) Recombinant factor IX. Thromb. Haemost. 78, 261-265.
78. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, et al. (2002) Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 42, 190-197.
79. Bjorkman S, Shapiro AD, Berntorp E. (2001) Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 7, 133-139.
80. Sheffield WP, Mamdani A, Hortelano G, Gataiance S, Eltringham-Smith L, Begbie ME, et al. (2004) Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br. J. Haematol. 126, 565-573.
81. Horn C, Steuber H, Metzner HJ,KuoW-P,Weimer T, Schulte S. (2010) Concept and structure model of factor IX albumin fusion proteins. Haemophilia 16(Suppl. 4), 36 [Abstract 08P18].
82. Metzner H, Weimer T, Raquet E, Nolte WM, Pragst I, Zollner S. (2010) Prolonged serum half-life of a recombinant, albuminfused, human coagulation factor IX (rIX-FP) in different animal species. Haemophilia 16(Suppl. 4), 40 [Abstract 08P41].
83. Campos IT,Amino R, SampaioCA, Auerswald EA, Friedrich T, LemaireHG, et al. (2002) Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor. Insect Biochem. Mol. Biol. 32, 991-997.
84. Campos IT, Tanaka-Azevedo AM, Tanaka AS. (2004) Identification and characterization of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma infestans (Hemiptera: Reduvildae). FEBS Lett. 577, 512-516.
85. Schmidbauer S, Nerlich C, Weimer T, Kronthaler U, Metzner H, Schulte S. (2009) Prevention of thrombotic events by Factor XIIa inhibitors. 53rd Annual Meeting Society of Thrombosis and Haemostasis Research, February 4-7, Vienna, Austria, A22 [Abstract FC9-3].
86. Zhao HL, Xue C, Wang Y, Li XY, Xiong XH, Yao XQ, et al. (2007) Circumventing the heterogeneity and instability of human serum albumin-interferon-a2b fusion protein by altering its orientation. J. Biotechnol. 131, 245-252.
87. Zhao HL, Xue C, Wang Y, Sun B, Yao XQ, Liu ZM. (2009) Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-a2b and HSA fusion protein increases its stability against mechanical and thermal stresses. Eur. J. Pharm. Biopharm. 72, 405-411. REFERENCES 177
88. Chou DK, Krishnamurthy R, Randolph, T.W, Carpenter JF, Manning MC. (2005) Effects of Tween 20 and Tween 80 on the stability of Albutropin1 during agitation. J. Pharm. Sci. 94, 1368-1381.
89. Zhao HL, Yao XQ, Xue C,Wang Y, Xiong XH, Liu ZM. (2008) Increasing the homogeneity, stability and activity of human serum albumin and interferon-a2b fusion protein by linker engineering. Protein Expr. Purif. 61, 73-77.
90. Schulte S. (2009) Half-life extension through albumin fusion technologies. Thromb. Res. 124(Suppl. 2), S6-S8.
91. Sheffield WP, Wilson B, Eltringham-Smith LJ, Gataiance S, Bhakta V. (2005) Recombinant albumins containing additional peptide sequences smaller than barbourin retain the ability of barbourin-albumin to inhibit platelet aggregation. Thromb. Haemost. 93, 914-921.
92. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. (2000) Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96, 2373-2378.
93. Fischer KG, Liebe V, Hudek R, Piazolo L, Haase KK, Borggrefe M, et al. (2003) Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb. Haemost. 89, 973-982.
94. Baker MP, Jones TD. (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr. Opin. Drug Discov. Dev. 10, 219-227.
95. De Groot AS, Scott DW. (2007) Immunogenicity of protein therapeutics. Trends Immunol. 28, 482-490.